J B Chemicals & Pharmaceuticals has received USFDA approval for the company's Abbreviated New Drug Application (ANDA) for Carbamazepine Extended Release Tablets USP 100 mg, 200 mg and 400 mg. (for
treatment of Epilepsy and Trigeminal Neuralgia). The product is a generic version of Tegretol XR tablet in the same strength of Novartis Pharmaceuticals Corp. According to IQVIA, US sales were
approximately USD 128 million.
The company plans to commercialize this product in Q3 of this financial year and is expected to boost the company's US sales.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
